Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer - overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression

Cancer statistics, 2012

(2012) Rebecca Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer

(2011) P N Munster et al.   BRITISH JOURNAL OF CANCER

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer

(2011) K Ted Thurn et al.   Future Oncology

Pharmacogenetics of Endocrine Therapy for Breast Cancer

(2010) Michaela J. Higgins et al.   Annual Review of Medicine

Manipulating Protein Acetylation in Breast Cancer: A Promising Approach in Combination with Hormonal Therapies?

(2010) Aurélien Linares et al.   JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY

Histone deacetylase inhibitor induced modulation of anti-estrogen therapy

(2009) Scott Thomas et al.   CANCER LETTERS

Protein Acetylation and Histone Deacetylase Expression Associated with Malignant Breast Cancer Progression

(2009) J. Suzuki et al.   CLINICAL CANCER RESEARCH

Beyond antiepidermal growth factor receptors and antiangiogenesis strategies for nonsmall cell lung cancer: exploring a new frontier

(2009) Randeep Sangha et al.   CURRENT OPINION IN ONCOLOGY

Epigenetics and cancer treatment

(2009) Lasse Sommer Kristensen et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Valproic acid restores ERα and antiestrogen sensitivity to ERα-negative breast cancer cells

(2009) N. Fortunati et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

HDAC2 regulates chromatin plasticity and enhances DNA vulnerability

(2009) D. C. Marchion et al.   MOLECULAR CANCER THERAPEUTICS

Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer

(2008) Florian R Fritzsche et al.   BMC CANCER

HDAC expression and clinical prognosis in human malignancies

(2008) Wilko Weichert   CANCER LETTERS

Selective Inhibition of Histone Deacetylase 2 Silences Progesterone Receptor-Mediated Signaling

(2008) E. Bicaku et al.   CANCER RESEARCH

Class I Histone Deacetylase Expression Has Independent Prognostic Impact in Human Colorectal Cancer: Specific Role of Class I Histone Deacetylases In vitro and In vivo

(2008) W. Weichert et al.   CLINICAL CANCER RESEARCH

Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status

(2008) Lorena Travaglini et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY